ABSTRACT
Importance Childhood obesity increases cardiometabolic risk during childhood among individuals aged 2-18 years. These cardiometabolic outcomes include glucose intolerance, dyslipidemia, hypertension, metabolic syndrome, and type 2 diabetes (T2D). In the current state of research, a comprehensive review identifying all early-life exposures and risk factors that could predict cardiometabolic risk in children is lacking.
Objective To identify and evaluate the predictive early-life risk factors during the first 1,000 days of life, including preconception, pregnancy and birth, and early infancy periods for cardiometabolic risk outcomes in childhood.
Evidence review The present systematic review of existing literature was conducted to revise and search selected electronic databases (Medline, EMBASE, WEB OF SCIENCE, SCOPUS, and Cochrane CENTRAL) for longitudinal studies published between the database’s inception and August 17, 2022. This systematic review protocol was registered to PROSPERO, CRD42022355152, and following the PRISMA guidelines. We selected articles that studied the risk factors in mothers, fathers and infants, from preconception to infancy, for childhood cardiometabolic outcomes between 2 and 18 years.
Findings In 68 studies, we identified 229 associations between exposures and childhood cardiometabolic outcomes namely glucose intolerance, dyslipidemia, hypertension, metabolic syndrome, and T2D. The majority of associations (n=162) were positively associated with cardiometabolic risk factors. Pregnancy and birth risk factors were the categories with the most reported associations (86%). Among them, the most frequently assessed characteristics were birth anthropometrics (n=75), sociodemographics data (n=47), and pregnancy complications factors (n=34). However, we only identified few risk factors during preconception. In infancy period, breastfeeding (n=16) and infant anthropometrics (n=15) were consistently associated with cardiometabolic outcomes. In all periods, the most studied associations were identified for hypertension and metabolic syndrome.
Conclusions and relevance Birth anthropometrics, sociodemographics, and pregnancy complication factors were the most frequently reported predictive factors associated with a higher risk for cardiometabolic outcomes in children, particularly hypertension and metabolic syndrome. These results of this study are useful for predicting the risk for childhood cardiometabolic outcomes and for the modifiable factors. They also may facilitate the design of approaches aimed at the alteration of several behaviours from birth to infancy, encompassing both the maternal and paternal influences, as well as the preconception to infancy transition period. Future studies evaluating early-life risk factors with scarce scientific evidence, such as paternal and preconception factors, are urgently needed.
Question What is the existing evidence of early-life risk factors during the first 1000 days of life that are associated with cardiometabolic dysfunction between 2 and 18 years?
Findings Birth anthropometrics, pregnancy complications, sociodemographics and lifestyle factors are the most frequently reported associated exposures with hypertension and metabolic syndrome in children.
Meaning Identifying early-life risk factors and changing behavior patterns throughout preconception and infancy can contribute to prevent metabolic diseases later in childhood.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
RG received funding from the Netherlands Organization for Health Research and Development (ZonMW, grant number 543003109). RG has received funding from the European Union Horizon 2020 research and innovation program under the ERA-NET Cofund action (No. 727565), European Joint Programming Initiative A Healthy Diet for a Healthy Life (JPI HDHL), EndObesity, ZonMW Netherlands (No. 529051026). SMB was supported by the KNAW Ter Meulen Grant/KNAW Medical Science Fund, Royal Netherlands Academy of Arts & Sciences, and by ILSI Europe. ASJK was supported by ISLI Europe. MCC acknowledges the support by the Spanish Ministry of Science and Innovation (MCIN) research grant (ref. PID2022-139475OB-I00) and the award from MCIN/AEI to the Institute of Agrochemistry and Food Technology (IATA-CSIC) as Centre of Excellence Severo Ochoa (CEX2021-001189-S MCIN/AEI /10.13039/ 501100011033). EFV was supported by a Predoctoral grant awarded by the Spanish Ministry of Science and Innovation and the European Social Fund Plus (ESF+) for the training of doctors within the framework of the State Plan for Scientific, Technical and Innovation Research 2021 - 2023. (ref. CEX2021-001189-S-20-1). FJRO was supported by the Spanish Government (Juan de la Cierva program, Ministry of Science and Innovation). This Project was executed in collaboration with the Early Nutrition and Long-term Health Task Force of the European Branch of the International Life Sciences Institute (ILSI Europe). Industry members of this task force are listed on the website www.ilsi.eu. For more information, please contact ILSI Europe by email info@ilsieurope.be or call +32 2 771.00.14. The opinions expressed herein, and the conclusion of the project are those of the authors and do not necessarily represent the view of ILSI Europe nor those of its member companies.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
